Courtney D. DiNardo, MD
AML Specialist
Specialities: Acute Myeloid Leukemia
Spoken languages: English
Specialities: Acute Myeloid Leukemia
Spoken languages: English
Dr. DiNardo's research focus is on analysis of isocitrate dehydrogenase (IDH) mutations, serum 2-hydroxyglutarate (2HG) levels, and patient outcomes in AML. Dr. DiNardo is the primary investigator of multiple novel IDH1 or IDH2-targeted therapeutic agents currently in clinical trials. Dr. DiNardo is also involved in the clinical development of the BCL2-inhibitor venetoclax (ABT-199) for myeloid malignancies. She is leading the study of venetoclax in combination with hypomethylating agent therapy for the treatment of newly diagnosed elderly AML patients.
MD Anderson Cancer Center: 1515 Holcombe Blvd, Houston, TX 77030, USA
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.